The overall ratings of 19 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Ultragenyx Pharmaceutical, Inc. (RARE) slips from a C to a D this week. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of RARE stock.

Alkermes Plc (ALKS) earns a D this week, moving down from last week’s grade of C. Alkermes Plc is a fully integrated biotechnology company committed to developing medicines that will improve patients’ lives. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ALKS stock.

Eagle Pharmaceuticals, Inc. (EGRX) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of EGRX stock.

This is a rough week for Radius Health Inc (RDUS). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of RDUS stock.

Slipping from a D to a F rating, Clovis Oncology, Inc. (CLVS) takes a hit this week. Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLVS stock.

Recro Pharma, Inc. (REPH) declines this week from a C to a D. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of REPH stock.

MiMedx Group, Inc. (MDXG) is having a tough week. The company’s rating falls from a C to a D. MiMedx Group, Inc. operates as a medical device company. The company also gets F’s in earnings growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MDXG stock.

TG Therapeutics, Inc. (TGTX) gets weaker ratings this week as last week’s D drops to a F. TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TGTX stock.

ZIOPHARM Oncology, Inc.’s (ZIOP) rating weakens this week, dropping to a D versus last week’s C. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

This week, CareDx, Inc.’s (CDNA) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CDNA stock.

This week, Synergy Pharmaceuticals, Inc. (SGYP) drops from a C to a D rating. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

VistaGen Therapeutics, Inc. (VTGN) slips from a C to a D this week. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of VTGN stock.

ContraFect Corp. (CFRX) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CFRX stock.

This week, ARCA biopharma, Inc.’s (ABIO) rating worsens to a F from the company’s D rating a week ago. ARCA biopharma, Inc. is a biopharmaceutical company whose main focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ABIO stock.

ESSA Pharma Inc’s (EPIX) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of EPIX stock.

BioCryst Pharmaceuticals, Inc. (BCRX) earns a F this week, moving down from last week’s grade of D. BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. The company also gets F’s in sales growth, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BCRX stock.

Cleveland BioLabs, Inc. (CBLI) is having a tough week. The company’s rating falls from a C to a D. Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from radiation and other stresses. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBLI stock.

This is a rough week for Aptose Biosciences Inc. (APTO). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of APTO stock.

Arena Pharmaceuticals, Inc. (ARNA) gets weaker ratings this week as last week’s D drops to a F. Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies offering medical advances and new options for patients. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARNA stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.